Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, +53

The Lancet

Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineVersus Fluorouracil +7

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, +24

The Lancet Oncology

Cetuximab Versus FolfiriOncologyClinical TrialsPathologyColorectal Cancer +7

Current Status of the Algae Production Industry in Europe: An Emerging Sector of the Blue Bioeconomy

Rita Araújo, Fatima Vázquez Calderón, Javier Sánchez, +13

Frontiers in Marine Science

Eu Bioeconomy StrategyEngineeringBioenergyAlgal BiotechnologyAlgal Biomass +14

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial

Dirk Sibbing, Dániel Aradi, Claudius Jacobshagen, +104

The Lancet

Percutaneous Coronary InterventionThrombosisCardiovascular DiseaseClinical TrialsAntiplatelet Treatment +9

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius, +20

The Lancet Oncology

Cetuximab Versus FolfiriGastrointestinal OncologyTumour DynamicsMedicineCancer Management +8

Skeletal muscle partial pressure of oxygen in patients with sepsis

Peter Boekstegers, Stephan Weidenhöfer, Thomas Kapsner, +1

Critical Care Medicine

Frequency of Thrombolytic Therapy in Patients With Acute Ischemic Stroke and the Risk of In-Hospital Mortality

Peter U. Heuschmann, Klaus Berger, B. Misselwitz, +7

Stroke

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Sebastian Stintzing, Pratyaksha Wirapati, Heinz‐Josef Lenz, +20

Annals of Oncology

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann, Jens T. Siveke, Hana Algül, +34

˜The œLancet. Gastroenterology & hepatology

Pancreatic CancerGastrointestinal OncologyMedicinePharmacologyPharmacotherapy +7

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, +16

British Journal of Cancer